Publicaties
2026
Wetenschappelijke publicaties
Essink, S. C. M., Lasys, T., Santa-Ana-Tellez, Y., Siiskonen, S. J., Weir, D. L., Zomerdijk, I. M., Groenwold, R. H. H., Saliete, I., Poplavska, E., Kurvits, K., De Bruin, M. L., & Gardarsdottir, H. (2026). Dispensing of benzodiazepines and benzodiazepine-related drugs in Estonia, Latvia and Lithuania: a cross-national drug utilisation study. Nordic Journal of Psychiatry, 80(4), 265-276. [DOI] [Repository]
Lasys, T., Essink, S. C. M., Santa-Ana-Tellez, Y., Siiskonen, S. J., Weir, D. L., Zomerdijk, I. M., Groenwold, R. H. H., Bruin, M. L. D., & Gardarsdottir, H. (2026). Impact of policy measures targeting benzodiazepines and Benzodiazepine-related drugs in Lithuania: interrupted time series analysis. European Journal of Clinical Pharmacology, 82(3), Article 68. [DOI] [Repository]
2025
Wetenschappelijke publicaties
Essink, S. C. M., Zomerdijk, I. M., Straus, S. M. J. M., Gardarsdottir, H., & De Bruin, M. L. (2025). Risk Minimisation Measures of Advanced Therapy Medicinal Products Authorised in the EU Between 2009 and 2023: A Cross-Sectional Study. Drug Safety, 48(9), 1005-1022. [DOI] [Repository]
Essink, S. C. M., Zomerdijk, I. M., Goedecke, T., Straus, S. M. J. M., Gardarsdottir, H., & De Bruin, M. L. (2025). Duration of Time Intervals for Risk Minimization Measure Effectiveness Studies. Clinical Pharmacology and Therapeutics, 117(4), 1106-1114. [DOI] [Repository]
2023
Wetenschappelijke publicaties
Essink, S. C. M., Zomerdijk, I. M., Straus, S. M. J. M., Gardarsdottir, H., & De Bruin, M. L. (2023). Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021. Drug Safety, 46(10), 1007-1020. [DOI] [Repository]